NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
GREENFebuxostat 80mg , 120mg Adenuric®
(Tablets ) 		Musculoskeletal and joint diseases, Long-term control of gout, 10.01.04
REDTirzepatide Mounjaro®
(Overweight and obesity) 		Central nervous system, Drugs used in the treatment of obesity, 04.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Cilostazol Cilostazol Cardiovascular System, Antithrombotic Drugs, Antiplatelet Drugs
Vascular Disease
Iloprost  Iloprost Cardiovascular System, Prostaglandins And Analogues
Vascular Disease
Inositol  Inositol Nicotinate Cardiovascular System, Lipid Modifying Drugs, Nicotinic Acid Derivatives
Vascular Disease
Lauromacrogol Lauromacrogol 400 Cardiovascular System, Sclerosants
Vascular Disease, Vein Malformations
Naftidrofuryl  Naftidrofuryl Oxalate Cardiovascular System, Vasodilators, Peripheral Vasodilators
Vascular Disease
Nifedipine Nifedipine Cardiovascular System, Calcium-Channel Blockers
Vascular Disease
OxerutinsOxerutins Cardiovascular System, Vasodilators, Flavonoids
Vascular Disease
Pentoxifylline  Pentoxifylline Cardiovascular System, Vasodilators, Peripheral Vasodilators
Vascular Disease
Prazosin Prazosin Cardiovascular System, Alpha-Adrenoceptor Blockers
Vascular Disease
SODIUM  Sodium Tetradecyl Sulfate Cardiovascular System, Sclerosants
Vascular Disease, Vein Malformations
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA DSU JAN 2024: Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors
MHRA DSU May 2023 Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease
MHRA DSU: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
NICE CG172: MI : cardiac rehabilitation and prevention of further cardiovascular disease